|
Q1 FY2026
As of Jun 30, 2026
|
Q4 FY2025
As of Mar 31, 2026
|
Q3 FY2025
As of Dec 31, 2025
|
Q2 FY2025
As of Sep 30, 2025
|
Q1 FY2025
As of Jun 30, 2025
|
Q4 FY2024
As of Mar 31, 2025
|
Q3 FY2024
As of Dec 31, 2024
|
Q2 FY2024
As of Sep 30, 2024
|
Q1 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Mar 31, 2024
|
Q3 FY2023
As of Dec 31, 2023
|
Q2 FY2023
As of Sep 30, 2023
|
Q1 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Mar 31, 2023
|
Q3 FY2022
As of Dec 31, 2022
|
Q2 FY2022
As of Sep 30, 2022
|
Q1 FY2022
As of Jun 30, 2022
|
Q4 FY2021
As of Mar 31, 2022
|
Q3 FY2021
As of Dec 31, 2021
|
Q2 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Litigation settlement receivable | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Current assets of discontinued operations (Note 6) | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Restricted cash, net of current portion | ||||||||||||||||||||
| Investments measured at fair value | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Noncurrent assets of discontinued operations (Note 6) | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Current portion of long-term debt (includes $6,000 and $6,000 accounted for under the fair value option at June 30, 2024 and March 31, 2024, respectively) | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Current liabilities of discontinued operations (Note 6) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Liability instruments measured at fair value | ||||||||||||||||||||
| Operating lease liabilities, noncurrent | ||||||||||||||||||||
| Long-term debt, net of current portion (includes $82,369 and $204,371 accounted for under the fair value option at June 30, 2024 and March 31, 2024, respectively) | ||||||||||||||||||||
| Income tax payable, noncurrent | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Noncurrent liabilities of discontinued operations (Note 6) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 722,668,062 and 720,352,386 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Shareholders’ equity attributable to Roivant Sciences Ltd. | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
